Oratec Interventions
This article was originally published in The Gray Sheet
Executive Summary
Initial public offering of 4 mil. shares at $14 each on April 5 grosses $56 mil. The Menlo Park, California firm markets the SpineCath intradiscal electrothermal therapy system and electrothermal arthroscopy system, and plans to use a portion of the IPO proceeds to expand marketing activities (1"The Gray Sheet" July 19, 1999, p. 11). Oratec shares trade on the Nasdaq exchange under the symbol "OTEC." Underwriters Merrill Lynch, J.P. Morgan and U.S. Bancorp Piper Jaffray hold an overallotment option for 600,000 additional shares
You may also be interested in...
Oratec IPO Proceeds To Expand Marketing Of Thermal Spine/Joint Treatment
Marketing activities for Oratec Interventions controlled thermal energy systems to treat spine and joint disorders will be expanded following a planned initial public offering, the firm says.
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.